CORPORATE OVERVIEW

AXON Dx™ is developing instruments and reagents that allow rapid, minimally invasive analysis of the CTCs shed by the primary and metastatic tumors. With a simple blood draw, the researcher will be able to identify and count the CTCs in a patient’s sample.

LEADERSHIP

Kent Murphy, PhD
President & CEO

Dr. Murphy is a recognized national leader in transitioning science into products. For the past 32 years, he has led research and development programs, product development efforts and successfully launched dozens of products that are used around the world in a variety of market applications. Kent has experience and proven success in leading and managing technology teams through research and development all the way through product launch and customer support. Dr. Murphy has built-up and sold numerous companies and created more than 400 jobs in rural, Southwestern Virginia.

Phil Couch, PhD
Chief Technology Officer

Dr. Couch received a Ph.D. in Electro-Optics from Cambridge University in 1989 and is a fellow of the Institute of Engineering Technology. He is an accomplished engineer and co-founder of several successful engineering companies, and brings Axon Dx over 30 years of experience in technology development. Dr. Couch’s expertise lies in a broad background of electronics development and related optical and mechanical design, and in the development of precision instrumentation for many purposes used in the defense, government, energy (oil & gas and electrical power), and medical sectors. Among many products he developed the first fiber optic Ethernet, which was widely deployed in critical infrastructure. Phil brings this wealth of experience to the healthcare field with AxonDx and to the development of the nCyte system.